Alzheimer's disease drug development pipeline: 2019.

Cummings, Jeffrey; Lee, Garam; Ritter, Aaron; Sabbagh, Marwan; Zhong, Kate

Cummings, Jeffrey; Lee, Garam; Ritter, Aaron; Sabbagh, Marwan; Zhong, Kate.

Afiliação

Cummings J; Department of Brain Health, University of Nevada, Las Vegas (UNLV), School of Integrated Health Sciences, Las Vegas, NV, USA.
Lee G; Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV, USA.
Ritter A; Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV, USA.
Sabbagh M; Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV, USA.
Zhong K; Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV, USA.

Alzheimers Dement (N Y) ; 5: 272-293, 2019.

Article em En | MEDLINE | ID: mdl-31334330

Palavras-chave

Adaptive design; Alzheimer's disease; Bayesian design; Biomarkers; Clinical trials; Drug development; Repurposed drugs

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Revista: Alzheimers Dement (N Y) Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google